Is complement a target for therapy in renal disease?

Kidney International

Volumn 54, Issue 5, 1998, Pages 1429-1436

  Mathieson, Peter W ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Glomerulonephritis; Immunotherapy; Soluble CR1; Treatment; Xenotransplantation

Indexed keywords

COMPLEMENT; COMPLEMENT INHIBITOR;

COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CYTOLYSIS; DRUG TARGETING; GLOMERULONEPHRITIS; HUMAN; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE INJURY; XENOTRANSPLANTATION;

EID: 0031727741     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00129.x     Document Type: Article

References (70)

1. MATSUSHITA M, FUJITA T: Activation of the classical complement pathway by mannose-binding protein in association with a novel Cls-like serine protease. J Exp Med 176:1497-1502, 1992
2. HATTORI R, HAMILTON KK, McEVER RP, SIMS PJ: Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 264: 9053-9060, 1989
3. PLATT JL, VERCELLOTTI GM, LINDMAN BJ, OEGEMA TR, BACH FH, DALMASSO AP: Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med 171:1363-1368, 1990
4. MARKS RM, TODD RF, WARD PA: Rapid induction of neutrophilendothelial adhesion by endothelial complement fixation. Nature 339:314-317, 1989
5. SIMS PJ: Interaction of human platelets with the complement system, in Platelet Immunobiology, Molecular and Clinical Aspects, edited by KUNICKI TJ, GEORGE JN, Philadelphia, J.B. Lippincott, 1989, pp 354-383
6. ADLER S, BAKER PJ, JOHNSON RJ, OCHI RF, PRITZL P, COUSER WG: Complement membrane attack complex stimulates production of oxygen metabolites by cultured rat mesangial cells. J Clin Invest 77:762-777, 1986
7. SCHONERMARK M, DEPPISCH R, RIEDASCH G, ROTHER K, HANSCH GM: Induction of mediator release from human glomerular mesangial cells by the terminal complement components C5b-9. Int Archs Allergy Appl Immunol 96:331-337, 1991
8. WILMER WA, KAUMAYA PT, EMBER JA, COSIO FG: Receptors for the anaphylatoxin C5a (CD88) on human mesangial cells. J Immunol 160:5646-5652, 1998
9. PEPYS MB: Role of complement in induction of antibody production in vivo. J Exp Med 140:126-145, 1974
10. DEMPSEY PW, ALLISON ME, AKKARAJU S, GOODNOW CC, FEARON DT: C3 days of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348-350, 1996
11. MORGAN BP, GASQUE P: Extrahepatic complement biosynthesis: Where, when and why? Clin Exp Immunol 107:1-7, 1997
12. SACKS SH, ZHOU W, SHEERIN NS: Complement synthesis in the injured kidney: Does it have a role in immune complex glomerulonephritis? J Am Soc Nephrol 7:2314-2319, 1996
13. PEAKE PW, CHENG H, CHARLESWORTH JA, PUSSELL BA: Presence of an intact alternative pathway of complement in the human kidney, (abstract) Nephrol 3(Suppl 1):S236, 1997
14. SONG D, ZHOU W, NEIL S, SACKS SH: Compartmental localisation of complement component transcripts in the normal human kidney, (abstract) Nephrol 3(Suppl 1):S235, 1997
15. COSIO FG, SEDMAK DD, MAHAN JD, NAHMAN NS: Localization of decay accelerating factor in normal and diseased kidneys. Kidney Int; 36:100-107, 1989
16. ENDOH M, YAMASHINA M, OHI H, FUNAHASHI K, IKUNO T, YASUGI T, ATKINSON JP, OKADA H.: Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin Exp Immunol 94:182-188, 1993
17. MATHIESON PW, FEARON DT, MOORE FD JR: Complement, in Transplantation Biology: Cellular and Molecular Aspects, edited by TILNEY NL, STROM TB, PAUL LC, Philadelphia, Lippincott-Raven Publishers, 1996, pp 163-173
18. COULPIER M, ANDREEV S, LEMERCIER C, DAUCHEL H, LEES O, FONTAINE M, RIPOCHE J: Activation of the endothelium by IL-1α and glucocorticoids results in major increase of complement C3 and factor B production and generation of C3a. Clin Exp Immunol 101:142-149. 1995
19. HOGASEN K, JANSEN JH, MOLLNES TE, HOVDENES J, HARBOE M: Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 95:1054-1061, 1995
20. LEVY M, HALBWACHS-MECARELLI L, GUBLER M-C, KOHOUT G, BENSENOUCI A, NIAUDET P, HAUPTMANN G, LESAVRE P: H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 30:949-956, 1986
21. HOGASEN K, JANSEN JH: Porcine membranoproliferative glomerulo-nephritis (MPGN) type II is reversed by factor H substitution therapy. (abstract) J Am Soc Nephrol 8:474A-475A, 1997
22. AULT BH, SCHMIDT BZ, FOWLER NL, KASHTAN CE, AHMED AE, VOGT BA, COLTEN HR: Human factor H deficiency-Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 272:25168-25175, 1997
23. MERI S, KOISTINEN V, MIETTINEN A, TORNROTH T, SEPPALA IJT: Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 175:939-950, 1992
24. THOMPSON RA, WINTERBORN MH: Hypocomplementaemia due to a genetic deficiency of β1H globulin. Clin Exp Immunol 46:110-119, 1981
25. ROBSON WL, LEUNG AK, FICK GH, McKENNA AI: Hypocomplementemia and leukocytosis in diarrhoea-associated hemolytic uremic syndrome. Nephron 62:296-299, 1992
26. WARWICKER P, GOODSHIP THJ, DOUNE, RL, PIRSON Y, NICHOLLS A, WARD RM, GOODSHIP JA: Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53:836-844, 1998 (editorial, p 1085)
27. DAY AJ, WILLIS AC, RIPOCHE J, SIM RB: Sequence polymorphism of human complement factor H. Immunogenetics 27:211-214, 1988
28. WARWICKER P, GOODSHIP THJ, GOODSHIP JA: Three new polymorphisms in the human complement factor H gene and promoter region. Immunogenetics 46:437-438, 1997
29. MATHIESON PW, PETERS DK: Are nephritic factors nephritogenic? Am J Kidney Dis 24:964-966, 1994
30. SISSONS JGP, WEST RJ, FALLOWS J, WILLIAMS DG, BOUCHER BJ, AMOS N, PETERS DK: The complement abnormalities of lipodystrophy. N Engl J Med 294:461-465, 1976
31. MATHIESON PW, PETERS DK: Lipodystrophy in MCGN type II: The clue to links between the adipocyte and the complement system. Nephrol Dial Transplant 12:1804-1806, 1997
32. MATHIKSON PW, WüRZNER R, OLIVEIRA DBG, LACHMANN PJ, PETERS DK: Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 177:1827-1831, 1993
33. MATHIESON PW, PRINS J, WÜRZNER R, OLIVEIRA DBG, LACHMANN PJ, PETERS DK: Nephritic factor and complement-mediated lysis of adipocytes. (abstract) Q J Med 87:584, 1994
34. DAVID S, BIANCONE L, CASERTA C, BUSSOLATI B, CAMBI V, CAMUSSI G: Alternative pathway complement activation induces proinflammatory activity in human proximal tubular cells. Nephrol Dial Transplant 12:51-56, 1997
35. CLYNES R, DUMITRU C, RAVETCH JV: Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279:1052-1054, 1998
36. WEISMAN HF, BARTOW T, LEPPO MK, MARSH HC JR, CARSON GR, CONCINO MF, BOYLE MP, ROUX KH, WEISFEHLDT ML, FEARON DT: Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146-151, 1990
37. HILL J, LINDSAY TF, ORTIZ F, YEH CG, HECHTMAN HB, MOORE FD: Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat.J Immunol 149:1723-1728, 1992
38. PEMBERTON M, ANDERSON G, VETVICKA V, JUSTUS DE, Ross GD: Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. J Immunol 150:5104-5113, 1993
39. COSIO FG, ZAGER RA, SHARMA HM: Atheroembolic renal disease causes hypocomplementaemia. Lancet ii:118-121, 1985
40. Case Records of the Massachusetts General Hospital: Case 34-1991. N Engl J Med 325:563-572, 1991
41. SEIFERT PS, MESSNER M, ROTH I, BHAKDI S: Analysis of complement C3 activation products in human atherosclerotic lesions. Atherosclerosis 91:155-162, 1991
42. SEIFERT PS, HUGO F, TRANUM-JENSEN J, ZAHRINGER U, MUHLY M, BHAKDI S: Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 172: 547-557, 1990
43. SEIFERT PS, HUGO F, HANSSON GK, BHAKDI S: Prelesional complement activation in experimental atherosclerosis. Lab Invest 60:747-754, 1989
44. MENNANDER A, TIISALA S, PAAVONEN T, HALTTUNEN J, HAYRY P: Chronic rejection of rat aortic allograft. II. Administration of cyclosporin induces accelerated allograft arteriosclerosis. Transplant Int 4:173-179, 1991
45. RAIJ L, DALMASSO AP, STALEY NA, FISH AJ: Renal injury in DOCA-salt hypertensive C5-sufficient and C5-deficiem mice. Kidney Int 36:582-592, 1989
46. GROGGEL GC. ADLER S, RENNKE HG, COUSER WG, SALANT DJ: Role of terminal complement pathway in experimental membranous nephropathy in the rabbit. J Clin Invest 72:1948-1957, 1983
47. BAKER PJ, OCHI RF, SCHULZE M, JOHNSON RJ, CAMPBELL C, COUSER WG: Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol 135:185-194, 1989
48. WANG Y, HU Q, MADRI JA, ROLLINS SA, CHODERA A, MATIS LA: Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 93:8563-8568, 1996
49. CORK LC, MORRIS JM, OLSON JL, KRAKOWKA S, SWIFT AJ, WINKELSTHIN JA: Membranoproliferative glomerulonephritis in dogs with a genetically determined deficiency of the third component of complement. Clin Immunol Immunopathol 60:455-470, 1991
50. LEHNER PJ, DAVIS KA, WALPORT MJ, COPE AP, WÜRZNER R, ORREN A, MORGAN BP, COHEN J: Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet 340:1379-1381, 1992
51. WESSELS MR, BUTKO P, MA M, WARREN HB, LAGE AL, CARROLL MC: Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 92:11490-11494, 1995
52. BOTTO M, DELL AGNOLA C, BYGRAVE AE, THOMPSON EM, COOK HT, PETRY F, Loos M, PANDOLFI PP, WALPORT MJ: Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genet 19:56-59, 1998
53. MATHIESON PW, PETERS DK: Deficiency and depletion of complement in the pathogenesis of nephritis and vasculitis. Kidney Int 44(Suppl 42): S13-S18, 1993
54. KORb LC, AHEARN JM: C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes. Complement deficiency and systemic lupus erythematosus revisited. J Immunol 158:4525-4528, 1997
55. MATHIESON PW, QASIM FJ, THIRU S, OLDROYD RG, OLIVEIRA DBG: Effects of decomplementation with cobra venom factor on experimental vasculitis. Clin Exp Immunol 97:474-476, 1994
56. FEARON DT: Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med 152:20-30, 1980
57. YOON S, FEARON DT: Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J Immunol 134:3332-3338, 1985
58. PRUITT SK, BALDWIN WM III, MARSH HC JR, LIN SS, YEH CG, BOLLINGER RR: The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 52:868-873, 1991
59. XIA W, FEARON DT, MOORE FD, SCHOEN FJ, ORTIZ F, KIRKMAN RL: Prolongation of guinea pig cardiac xenograft survival in rats by soluble human complement receptor type 1. Transplant Proc 24:479-480, 1992
60. PRUITT SK, BOLLINGER RR: The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J Surg Res 50:350-355, 1991
61. ZEHR KJ, HWRSKOWITZ A, LEE PC, KUMAR P, GILLINOV AM, BAUMGARTNER WA: Neutrophil adhesion and complement inhibition prolongs survival of cardiac xenografts in discordant species. Transplantation 57:900-906, 1994
62. COUSER WG, JOHNSON RJ, YOUNG, BA, YEH G, TOTH CA, RUDOLPH AR: The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 5:1888-1894, 1995
63. MIYATA T, FUJITA Y, INAGI R, INOUE I, SUGIYAMA S, MAEDA K: Effectiveness of nafamostat mesilate on glomerulonephritis in immune-complex diseases. Lancet 341:1353, 1943
64. KILGORE KS, NAYLOR KB, TANHEHCO EJ, PARK JL, BOOTH EA, WASHINGTON RA, LUCCHESI BR: The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart. J Pharmacol Exp Ther 285:987-994, 1998
65. DALMASSO AP, VERCELLOTTI GM, PLATT JL, BACH FH: Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Transplantation 52:530-533, 1991
66. MORAN P, BEASLEY H, GORRELL A, MARTIN E, GRIBLING P, FUCHS H, GILLETT N, BURTON LE, CARAS IW: Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J Immunol 149:1736-1743, 1992
67. NANGAKU M, QUIGG RJ, SHANKLAND SJ. OKADA N, JOHNSON RJ, COUSER WG: Overexpression of Crry protects mesangial cells from complement-mediated injury. J Am Soc Nephrol 8:223-233, 1997
68. LEENAERTS PL, HALL BM, VAN DAMME BJ, DAHA MR, VANRENTERGHEM YF: Active Heymann nephritis in complement component C6 deficient rats. Kidney Int 47:1604-1614, 1995
69. BRANDT J, PIPPIN J, SCHULZE M, HANSCH GM, ALPERS CE, JOHNSON RJ, GORDON K, COUSER WG: Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 49:335-343, 1996
70. PELLAS TC, BOYAR W, VAN OOSTRUM J, WASVARY J, FRYER LR, PASTOR G, SILLS M, BRAUNWALDER A, YARWOOD DR, KRAMER R, KIMBLE E, HADALA J, HASTON W, MOREIRA-LUDEWIG R, UZIEL-FUSI S, PETERS P, BILL K, WENNOGLE LP: Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo. J Immunol 160: 5616-5621, 1998